

1 **Restriction Spectrum Imaging as a quantitative biomarker for prostate cancer with**
2 **reliable positive predictive value**

3
4 Mariluz Rojo Domingo^{1,2}, Deondre D Do^{1,2}, Christopher C Conlin³, Aditya Bagrodia⁴,
5 Tristan Barrett⁵, Madison T Baxter², Matthew Cooperberg⁶, Felix Feng⁷, Michael E Hahn³,
6 Mukesh Harisinghani⁸, Gary Hollenberg⁹, Juan Javier-Desloges⁴, Karoline Kallis², Sophia
7 Kamran¹⁰, Christopher J Kane⁴, Dimitri Kessler⁵, Joshua Kuperman², Kang-Lung Lee⁵,
8 Jonathan Levine⁶, Michael A Liss¹¹, Daniel JA Margolis¹², Ian Matthews², Paul M Murphy³,
9 Nabih Nakrour⁸, Michael Ohliger¹³, Courtney Ollison², Thomas Osinski¹⁴, Anthony James
10 Pamatmat¹⁴, Isabella R Pompa⁸, Rebecca Rakow-Penner³, Jacob L Roberts⁴, Karan
11 Santhosh¹⁵, Ahmed S Shabaik¹⁶, Yuze Song^{2,17}, David Song¹⁴, Clare M. Tempany⁸, Natasha
12 Wehrli¹², Eric P. Weinberg⁹, Sean Woolen¹³, George Xu², Allison Y Zhong², Anders M
13 Dale^{3,18,19}, Tyler M Seibert^{1,2,3}

14
15 ¹Department of Bioengineering, University of California San Diego, La Jolla, CA, USA

16 ²Department of Radiation Medicine, University of California San Diego, La Jolla, CA, USA

17 ³Department of Radiology, University of California San Diego, La Jolla, CA, USA

18 ⁴Department of Urology, University of California San Diego, La Jolla, CA, USA

19 ⁵Department of Radiology, University of Cambridge, Cambridge, United Kingdom

20 ⁶Department of Urology, University of California San Francisco, San Francisco, CA, USA

21 ⁷Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA

22 ⁸Department of Radiology, Massachusetts General Hospital, Boston, MA, USA

23 ⁹Department of Clinical Imaging Sciences, University of Rochester Medical Center, Rochester, NY, USA

24 ¹⁰Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

25 ¹¹Department of Urology, University of Texas Health Sciences Center San Antonio, San Antonio, TX, USA

26 ¹²Department of Radiology, Cornell University, Ithaca, NY, USA

27 ¹³Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco,
28 CA, USA

29 ¹⁴Department of Urology, University of Rochester Medical Center, Rochester, NY, USA

30 ¹⁵Department of Computer Science, University of California San Diego, La Jolla, CA, USA

31 ¹⁶Department of Pathology, University of California San Diego, La Jolla, CA, USA

32 ¹⁷Department of Electrical and Computer Engineering, University of California San Diego, La Jolla, CA, USA

33 ¹⁸Department of Neurosciences, University of California San Diego, La Jolla, CA, USA

34 ¹⁹Halicioğlu Data Science Institute, University of California San Diego, La Jolla, CA, USA

35 **Abstract**

36 Background and Objective. Positive predictive value of PI-RADS for clinically significant
37 prostate cancer (csPCa, grade group [GG] \geq 2) varies widely between institutions and
38 radiologists. The Restriction Spectrum Imaging restriction score (RSIrs) is a metric
39 derived from diffusion MRI that could be an objectively interpretable biomarker for
40 csPCa.

41 Methods. In patients scanned for suspected or known csPCa at 7 centers, we calculated
42 patient-level csPCa probability based on maximum SIs in the prostate, without relying
43 on subjectively defined lesions. We used area under the ROC curve (AUC) to compare
44 patient-level csPCa detection for SIs, ADC, and PI-RADS. Finally, we combined SIs
45 with clinical risk factors via multivariable regression, training in a single-center cohort
46 and testing in an independent, multi-center dataset.

47 Key Findings and Limitations. Among all patients (n=1892), probability of csPCa
48 increased with higher SIs. GG \geq 4 csPCa was most common in patients with very high
49 SIs. Among biopsy-naïve patients (n=877), AUCs for GG \geq 2 vs. non-csPCa were 0.73
50 (0.69-0.76), 0.54 (0.50-0.57), and 0.75 (0.71-0.78) for SIs, ADC, and PI-RADS,
51 respectively. SIs significantly outperformed ADC (p <0.01) and was comparable to PI-
52 RADS (p =0.31). The combination of SIs and PI-RADS outperformed either alone.
53 Combining SIs with PI-RADS, age, and PSA density in a multivariable model achieved
54 the best discrimination of csPCa.

55 Conclusions and Clinical Implications. SIs is an accurate and reliable quantitative
56 biomarker that performs better than conventional ADC and comparably to expert-
57 defined PI-RADS for patient-level detection of csPCa. SIs provides objective estimates
58 of probability of csPCa that do not require radiology expertise.
59

60 Introduction

61 Multiparametric magnetic resonance imaging (mpMRI) has reduced unnecessary
62 biopsies, decreased overdiagnosis of indolent disease, and improved detection of
63 clinically significant prostate cancer (csPCa, grade group (GG) ≥ 2)¹⁻³. In clinical practice,
64 mpMRI is interpreted qualitatively using the Prostate Imaging Reporting & Data System
65 (PI-RADS v2.1). While negative predictive value (NPV) using PI-RADS is high and fairly
66 consistent⁴, positive predictive value (PPV) for csPCa varies widely across institutions
67 and between radiologists^{5,6}. The heavy dependence on user expertise and the variability
68 across readers leads to healthcare disparities by limiting access to high-quality MRI. A
69 quantitative imaging biomarker could help move prostate MRI toward objective
70 interpretation and yield consistent PPV for csPCa-positive biopsy.

71
72 Diffusion-weighted MRI is the most important mpMRI sequence for csPCa detection in
73 the PI-RADS system⁷. However, the conventional quantitative metric for diffusion-
74 weighted MRI, apparent diffusion coefficient (ADC), is based on an unrealistically
75 simplistic model that assumes uniform free diffusion of water molecules in the prostate.
76 Restriction Spectrum Imaging (RSI) is a more advanced diffusion-weighted MRI
77 technique that yields a quantitative biomarker (RSI restriction score, or RSIrs) designed
78 to highlight csPCa. In prior retrospective single-center studies, we showed that RSIrs
79 reduced the number of false positives compared to ADC and outperformed ADC for
80 voxel-level and patient-level detection of csPCa^{8,9}. A prospective study found that
81 radiation oncologists were much more accurate in outlining csPCa on MRI when using
82 RSIrs than when using conventional MRI alone¹⁰.

83
84 In this study, we evaluate RSIrs as a generalizable tool for patient-level csPCa
85 detection—with objective interpretation—in data from multiple imaging protocols,
86 scanners, vendors, and centers. We also evaluate the accuracy of RSIrs in challenging
87 scenarios: csPCa detection among younger patients¹¹ and within the transition zone
88 (TZ)^{12,13}. Lastly, we investigate integrating RSIrs with other clinical parameters, such as
89 age and prostate specific antigen density (PSAD) to yield objective estimates of csPCa
90 probability that could serve as a standardized reference for assessing prostate MRIs,
91 independent of radiologist expertise.

92

93 Methods

94 Study Population

95 The data for this study come from seven imaging centers participating in the Quantitative
96 Prostate Imaging Consortium (QPIC): the Center for Translational Imaging and Precision
97 Medicine at the University of California San Diego (CTIPM), UC San Diego Health (UCSD),
98 University of California San Francisco (UCSF), Harvard University affiliated
99 Massachusetts General Hospital (MGH), University of Rochester Medical Center
100 (URMC), University of Texas Health Sciences Center San Antonio (UTHSCSA), and
101 University of Cambridge (Cambridge). The study was approved by each center's
102 institutional review board (IRB). Data were collected prospectively at UCSD, UTHSCSA,
103 and Cambridge; data were collected retrospectively at the other centers. Participants at
104 UTHSCSA and Cambridge provided written informed consent, while a waiver of consent
105 was approved by the respective IRBs at the other centers for secondary use of routine
106 clinical data. We included individuals aged ≥ 18 who underwent an MRI for suspected or

107 known csPCa between January of 2016 and March of 2024. Patients were excluded in the
108 event of prior treatment of prostate cancer (PCa) or if there was no available biopsy result
109 from within 6 months of a positive MRI scan (PI-RADS ≥ 3). Patients with metal implants
110 were also excluded because of the potential to cause significant artifact in MRI.
111 Diagnosis of csPCa was confirmed on biopsy histopathology per clinical routine at each
112 center.

113

114 RSI data acquisition, processing, and modeling

115 Image post-processing for RSI data included correction for background noise, gradient
116 nonlinearities, and eddy currents¹⁴⁻¹⁶. Data acquired at CTIPM were also corrected for
117 distortion caused by B_0 inhomogeneity¹⁷. Automated prostate contours were obtained
118 using an FDA-cleared commercial product (OnQ Prostate, CorTechs.ai, San Diego, CA).

119 In the RSI framework, diffusion MRI signal is modeled as a combination of exponential
120 decays corresponding to four diffusion microcompartments (intracellular, extracellular,
121 free diffusion, and vascular flow) within each voxel¹⁸. The RSIrs biomarker is the
122 intracellular signal at a given voxel normalized by median T_2 -weighted signal in the
123 prostate and multiplied by 1,000 for convenience. RSIrs is highest where intracellular
124 diffusion restriction (hypercellularity) and nucleus-to-cytoplasm ratio are high, both
125 features characteristic of csPCa. Maximum RSIrs is the highest RSIrs value within the
126 prostate^{8-10,14,18-20}. Additional details are provided in Supplementary Table 1.

127 Patient-level detection of csPCa

128 For objective and reliable interpretation of MRI results independent of radiologist
129 expertise, risk of csPCa must be determined without subjective lesion delineation. Thus,
130 we assessed csPCa classification performance using maximum RSIrs, which only
131 requires automated segmentation of the prostate. We plotted histograms of maximum
132 RSIrs by csPCa status and obtained the probability (PPV) of csPCa and high-grade csPCa
133 for RSIrs strata by dividing the number of GG ≥ 2 and GG ≥ 3 cases, respectively, by the total
134 number of patients for each bin. Bins spanned 50 RSIrs units, and adjacent bins were
135 combined for illustration purposes if PPV were similar. Pathologic GG is a major
136 prognostic factor for patients with csPCa²¹: GG2 cancer with low-volume Gleason
137 pattern 4 generally poses little risk and may be safely monitored²², while GG3-5 cancers
138 are more critical to detect and treat early because of their higher metastatic potential²³.
139 We showed the GG distribution within each RSIrs stratum among patients who were
140 biopsy-naïve at time of MRI.

141 To evaluate patient-level detection of csPCa over a range of possible operating points,
142 we plotted the receiver operating characteristic (ROC) curves with csPCa as the outcome
143 of interest. For comparison, we used minimum ADC within the prostate and the highest
144 PI-RADS category for each patient. PI-RADS reporting was performed per clinical routine
145 by experienced, board-certified, fellowship-trained radiologists. We calculated the area
146 under the curve (AUC) with 95% confidence intervals from 10,000-bootstraping
147 samples and compared bootstrap AUC differences ($\alpha=0.05$). We repeated these
148 analyses stratified by GG (i.e., GG2 vs. non-csPCa, GG3 vs. non-csPCa, etc.). We also
149 evaluated csPCa detection in challenging subsets: patients with TZ lesions and patients
150 with age < 60 years.

151 Multivariable integrated risk

152 We used multivariable logistic regression models to combine RSIs with other routinely
153 available clinical risk factors that physicians may consider in biopsy decisions. We
154 incorporated age, prostate-specific antigen (PSA) level, and PSA density (PSAD). We also
155 evaluated combining these objective variables with expert interpretation of MRI (PI-
156 RADS). Black or African American men are much more likely to develop PCa^{24,25}, so we
157 evaluated self-reported race as an additional predictor. We trained the models using
158 UCSD Health data collected on two GE Healthcare Discovery MR750 scanners. The
159 models were tested in remaining patients from all cohorts who were biopsy-naïve at time
160 of MRI and who received a biopsy after MRI. We tested the multivariable models for
161 patient-level detection of csPCa (csPCa vs. non-csPCa) and by GG. We evaluated
162 models with different predictors: (1) age and PSA, which are available before an MRI
163 scan; (2) age and PSAD, which can be computed once MRI is performed; (3) age, PSAD,
164 and RSIs; (4) RSIs and PI-RADS, to see if better than either alone; (5) age, PSAD, RSIs,
165 and PI-RADS; and (6) age, race, PSAD, RSIs, and PI-RADS.

166

167 **Results**

168 Patient-level detection of csPCa

169 1892 patients met the criteria for inclusion (Table 1). Data were acquired using 7 distinct
170 acquisition protocols, 2 scanner vendors, 3 scanner models, and 17 MRI scanners
171 (Supplementary Table 2).

172

173 Probability of csPCa increased with higher RSIs. High-grade (GG4-5) csPCa was
174 proportionally more common among those with highest RSIs (Figure 1). For RSIs>500,
175 there was 80% probability of csPCa found on biopsy and 64% probability of GG≥3 PCa,
176 whereas for RSIs<200, patients had 12% probability of csPCa and only 6% probability of
177 GG≥3 PCa. RSIs and ADC maps are shown for three representative patients in Figure 2.

178

179 ROC curve analysis demonstrated that RSIs was superior to ADC and comparable to PI-
180 RADS for patient-level detection of csPCa (Figure 3). Among 877 biopsy-naïve patients
181 who underwent biopsy after MRI, median AUC for GG≥2 vs. non-csPCa was 0.73 (0.69-
182 0.76) for RSIs, 0.54 (0.50-0.57) for ADC, and 0.75 (0.71-0.78) for PI-RADS. RSIs
183 significantly outperformed ADC ($p<0.01$) and was comparable to PI-RADS ($p=0.31$).

184

185 When comparing GG≥3 to non-csPCa (i.e., excluding GG2), median AUCs were 0.76
186 (0.72-0.80) for RSIs, 0.55 (0.50-0.60) for ADC, and 0.79 (0.76-0.82) for PI-RADS. RSIs
187 significantly outperformed ADC ($p<0.01$) and was comparable to PI-RADS ($p=0.14$). Both
188 RSIs and PI-RADS showed partial specificity for high-grade csPCa, with higher
189 performance for detection of GG3 and GG4-5 than for GG2 (Figure 3 and Supplementary
190 Table 3).

191

192 RSIs performed similarly to expert PI-RADS in patients with lesions in the TZ ($p=0.90$) and
193 PZ ($p=0.07$). RSIs performed similarly to PI-RADS in patients <60 years ($p=0.12$) and >60
194 years ($p=0.11$). Subset analyses by race were limited by small sample size for most
195 groups (Supplementary Table 3).

196 Multivariable integrated risk

197 Models to combine predictor variables were trained in 554 patients, including 232 with
198 no biopsy but presumed free of csPCa (PI-RADS 1-2 and PSAD \leq 0.15)²⁶ and excluding
199 patients that did not have a PI-RADS score available. Models were tested in an
200 independent dataset from multiple institutions with 664 patients, all biopsy naïve before
201 MRI and with biopsy confirmation of csPCa status. The combination of RSIs and PI-RADS
202 outperformed either alone ($p<0.01$ and $p=0.01$, respectively), and a model of age, PSAD,
203 PI-RADS, and RSIs achieved the best discrimination of csPCa, outperforming RSIs
204 alone and PI-RADS alone ($p<0.01$; Table 2). Addition of race did not significantly improve
205 performance in any of the multivariable models.

206

207 **Discussion**

208 We assessed RSIs as an objective MRI biomarker for detecting csPCa at the patient
209 level. In contrast to ADC, which typically becomes clinically useful after a radiologist
210 identifies a suspicious lesion, RSIs assessed automatically within the entire prostate
211 performed comparably to expert PI-RADS for patient-level detection of csPCa in a large,
212 heterogeneous and multi-center dataset. Moreover, RSIs performs best for the high-
213 grade cancers that are also most important to detect. An automated measurement of
214 RSIs can give physicians and patients an objective and reliable estimate of the likelihood
215 of csPCa or high-grade csPCa.

216

217 Subspecialist radiologists are often at elite centers that provide care for only a small
218 proportion of patients. A quantitative biomarker could contribute to making accurate
219 prostate MRI accessible to patients who do not receive their care at these elite centers.
220 The PPV of RSIs is inherently reproducible for a given scan, as it is calculated objectively
221 from the MRI. Use of RSIs, then, could make prostate MRI more reliable and more readily
222 interpretable for referring physicians and their patients. By addressing the variable PPV
223 of PI-RADS and reducing dependence on reader expertise, implementation of objective
224 biomarkers could increase health equity in the PCa diagnostic pathway.

225

226 RSIs requires only an RSI MRI acquisition lasting 2-3 minutes and a T_2 -weighted MRI
227 acquisition (another 2-3 minutes). Thus, 4-6 minutes of scan time can yield an
228 automated RSIs biomarker with performance comparable to expert radiologists'
229 evaluations of a full PI-RADS mpMRI scan. RSI acquisitions are compatible with standard
230 clinical scanners and do not require administration of intravenous contrast. Installing the
231 RSI acquisition protocols on modern scanners involves simply saving protocol files on
232 the scanner. Calculation of RSIs can be performed by software on a desktop personal
233 computer.

234

235 Maximum RSIs is a quantitative biomarker that is readily interpretable. Thus, use of
236 RSIs could establish a floor for performance of csPCa detection regardless of available
237 radiology expertise. Radiologist interpretation of MRI remains important for evaluation of
238 secondary questions: extraprostatic extension, tumor proximity to the neurovascular
239 bundles, and seminal vesicle involvement. However, these latter questions are mostly
240 relevant only after a biopsy-confirmed diagnosis of csPCa is established and therefore
241 apply to a smaller subset of patients. For the initial question of whether csPCa is likely to
242 be found on biopsy, RSIs performs comparably to expert-defined PI-RADS, and the
243 combination of both is better than either alone.

244 We focused this study on patient-level csPCa detection. Another important role of MRI is
245 tumor localization for targeted biopsy²⁷⁻³² and radiotherapy planning³³⁻³⁵. Radiologist-
246 defined lesion segmentations were not available to perform lesion-level analysis of this
247 large dataset. The commercial software our centers use to delineate biopsy targets does
248 not permit export of those segmentations and automatically deletes them to make room
249 for future studies. In any event, expert-defined lesions are subjectively identified, thus
250 undermining the primary goal of the study to consider approaches independent of
251 radiologist expertise. Prior work, though, has shown that RSIs maps are useful for
252 localization of csPCa (Figure 2). There is a strong correlation between RSI and csPCa on
253 whole-mount histopathology, and RSIs is superior to ADC for voxel-level detection of
254 csPCa^{9,36}. Further, a prospective study evaluated radiation oncologists' ability to
255 delineate csPCa on MRI; these non-radiologists were much more accurate when using
256 RSIs maps vs. conventional MRI alone, confirming that RSIs maps reflect the location
257 of csPCa and make it more apparent to non-experts¹⁰.

258

259 Automated and quantitative MRI approaches may help alleviate the growing shortage of
260 expert radiologists relative to an anticipated surge in PCa diagnoses³⁷. Other MRI
261 biomarkers have also shown potential clinical utility in prior studies^{38,39}. To our
262 knowledge, the present study is the largest and most comprehensive validation of a
263 quantitative MRI biomarker for patient-level csPCa detection. Ongoing research
264 evaluates whether incorporating RSIs into radiomics-based analysis and deep-learning
265 artificial intelligence tools could further enhance detection performance.

266

267 Our study has some limitations. First, biopsy techniques are prone to sampling error and
268 therefore represent an imperfect gold standard. Nonetheless, most patients here
269 underwent both systematic and targeted biopsy, which is the current clinical standard
270 and captures most csPCa^{4,28,29,40}. Consistent with clinical guidelines, patients with non-
271 suspicious prostate MRI typically did not undergo biopsy, raising the possibility of false
272 negatives on PI-RADS, though the risk of this is low⁴. Also, patients with hip implants
273 were excluded from this study; the effect of metal artifact on RSIs is the subject of
274 ongoing research.

275

276 **Conclusions**

277 In heterogeneous data from multiple imaging centers, RSIs proved to be a quantitative
278 imaging biomarker that performs comparably to expert-defined PI-RADS for patient-level
279 detection of csPCa. With only 4-6 minutes of scan time on standard clinical MRI
280 platforms, RSIs gives objective estimates of probability of csPCa, thus addressing the
281 current clinical challenge of unreliable PPV with PI-RADS.

282

283 **References**

- 284 1. Filson CP, Natarajan S, Margolis DJA, et al. Prostate cancer detection with magnetic
285 resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
286 *Cancer*. 2016;122(6):884-892. doi:10.1002/cncr.29874
- 287 2. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-
288 guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
289 *JAMA*. 2015;313(4):390-397. doi:10.1001/jama.2014.17942
- 290 3. Yaxley AJ, Yaxley JW, Thangasamy IA, Ballard E, Pokorny MR. Comparison between
291 target magnetic resonance imaging (MRI) in-gantry and cognitively directed
292 transperineal or transrectal-guided prostate biopsies for Prostate Imaging-
293 Reporting and Data System (PI-RADS) 3-5 MRI lesions. *BJU Int*. 2017;120 Suppl 3:43-
294 50. doi:10.1111/bju.13971
- 295 4. Sathianathen NJ, Omer A, Harriss E, et al. Negative Predictive Value of
296 Multiparametric Magnetic Resonance Imaging in the Detection of Clinically
297 Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era:
298 A Systematic Review and Meta-analysis. *Eur Urol*. 2020;78(3):402-414.
299 doi:10.1016/j.eururo.2020.03.048
- 300 5. Westphalen AC, McCulloch CE, Anaokar JM, et al. Variability of the Positive
301 Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the
302 Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. *Radiology*.
303 2020;296(1):76-84. doi:10.1148/radiol.2020190646
- 304 6. Sonn GA, Fan RE, Ghanouni P, et al. Prostate Magnetic Resonance Imaging
305 Interpretation Varies Substantially Across Radiologists. *Eur Urol Focus*.
306 2019;5(4):592-599. doi:10.1016/j.euf.2017.11.010
- 307 7. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data
308 System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System
309 Version 2. *Eur Urol*. 2019;76(3):340-351. doi:10.1016/j.eururo.2019.02.033
- 310 8. Zhong AY, Digma LA, Hussain T, et al. Automated Patient-level Prostate Cancer
311 Detection with Quantitative Diffusion Magnetic Resonance Imaging. *Eur Urol Open*
312 *Sci*. 2023;47:20-28. doi:10.1016/j.euros.2022.11.009
- 313 9. Feng CH, Conlin CC, Batra K, et al. Voxel-level Classification of Prostate Cancer on
314 Magnetic Resonance Imaging: Improving Accuracy Using FOUR-COMPARTMENT
315 Restriction Spectrum Imaging. *J Magn Reson Imaging*. 2021;54(3):975-984.
316 doi:10.1002/jmri.27623
- 317 10. Lui AJ, Kallis K, Zhong AY, et al. ReIGNITE Radiation Therapy Boost: A Prospective,
318 International Study of Radiation Oncologists' Accuracy in Contouring Prostate
319 Tumors for Focal Radiation Therapy Boost on Conventional Magnetic Resonance
320 Imaging Alone or With Assistance of Restriction Spectrum Imaging. *Int J Radiat*
321 *Oncol Biol Phys*. 2023;117(5):1145-1152. doi:10.1016/j.ijrobp.2023.07.004


- 322 11. Boschheidgen M, Albers P, Schlemmer HP, et al. Multiparametric Magnetic
323 Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results
324 from the First Screening Round of the PROBACE Trial. *Eur Urol*. Published online
325 October 2023;S0302283823031585. doi:10.1016/j.eururo.2023.09.027
- 326 12. Thai JN, Narayanan HA, George AK, et al. Validation of PI-RADS Version 2 in
327 Transition Zone Lesions for the Detection of Prostate Cancer. *Radiology*.
328 2018;288(2):485-491. doi:10.1148/radiol.2018170425
- 329 13. Gielchinsky I, Scheltema MJ, Cusick T, et al. Reduced sensitivity of multiparametric
330 MRI for clinically significant prostate cancer in men under the age of 50. *Res Rep*
331 *Urol*. 2018;10:145-150. doi:10.2147/RRU.S169017
- 332 14. White NS, McDonald CR, Farid N, et al. Diffusion-Weighted Imaging in Cancer:
333 Physical Foundations and Applications of Restriction Spectrum Imaging. *Cancer*
334 *Res*. 2014;74(17):4638-4652. doi:10.1158/0008-5472.CAN-13-3534
- 335 15. Zhuang J, Hrabe J, Kangarlu A, et al. Correction of eddy-current distortions in
336 diffusion tensor images using the known directions and strengths of diffusion
337 gradients. *J Magn Reson Imaging*. 2006;24(5):1188-1193. doi:10.1002/jmri.20727
- 338 16. Karunamuni RA, Kuperman J, Seibert TM, et al. Relationship between kurtosis and
339 bi-exponential characterization of high b-value diffusion-weighted imaging:
340 application to prostate cancer. *Acta Radiol*. 2018;59(12):1523-1529.
341 doi:10.1177/0284185118770889
- 342 17. Holland D, Kuperman JM, Dale AM. Efficient correction of inhomogeneous static
343 magnetic field-induced distortion in Echo Planar Imaging. *NeuroImage*.
344 2010;50(1):175-183. doi:10.1016/j.neuroimage.2009.11.044
- 345 18. Conlin CC, Feng CH, Rodriguez-Soto AE, et al. Improved Characterization of
346 Diffusion in Normal and Cancerous Prostate Tissue Through Optimization of
347 Multicompartmental Signal Models. *J Magn Reson Imaging*. 2021;53(2):628-639.
348 doi:10.1002/jmri.27393
- 349 19. White NS, Dale AM. Distinct effects of nuclear volume fraction and cell diameter on
350 high b-value diffusion MRI contrast in tumors: Diffusion in Tumor Cells. *Magn Reson*
351 *Med*. 2014;72(5):1435-1443. doi:10.1002/mrm.25039
- 352 20. White NS, Leergaard TB, D'Arceuil H, Bjaalie JG, Dale AM. Probing tissue
353 microstructure with restriction spectrum imaging: Histological and theoretical
354 validation. *Hum Brain Mapp*. 2013;34(2):327-346. doi:10.1002/hbm.21454
- 355 21. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological
356 Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic
357 Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
358 *Am J Surg Pathol*. 2016;40(2):244-252. doi:10.1097/PAS.0000000000000530

- 359 22. Hamdy Freddie C., Donovan Jenny L., Lane J. Athene, et al. Fifteen-Year Outcomes
360 after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. *N Engl J Med.*
361 2023;388(17):1547-1558. doi:10.1056/NEJMoa2214122
- 362 23. Menne Guricová K, Groen V, Pos F, et al. Risk Modeling for Individualization of the
363 FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With
364 Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys.* 2024;118(1):66-73.
365 doi:10.1016/j.ijrobp.2023.07.044
- 366 24. Lillard Jr JW, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with
367 prostate cancer: A literature review. *Cancer.* 2022;128(21):3787-3795.
368 doi:10.1002/cncr.34433
- 369 25. Pagadala MS, Lynch J, Karunamuni R, et al. Polygenic risk of any, metastatic, and
370 fatal prostate cancer in the Million Veteran Program. *J Natl Cancer Inst.*
371 2023;115(2):190-199. doi:10.1093/jnci/djac199
- 372 26. Norris JM, Carmona Echeverria LM, Bott SRJ, et al. What Type of Prostate Cancer Is
373 Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An
374 Analysis from the PROMIS Cohort. *Eur Urol.* 2020;78(2):163-170.
375 doi:10.1016/j.eururo.2020.04.029
- 376 27. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy
377 for Prostate-Cancer Diagnosis. *N Engl J Med.* 2018;378(19):1767-1777.
378 doi:10.1056/NEJMoa1801993
- 379 28. Rouvière O, Puech P, Renard-Penna R, et al. Use of prostate systematic and
380 targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-
381 FIRST): a prospective, multicentre, paired diagnostic study. *Lancet Oncol.*
382 2019;20(1):100-109. doi:10.1016/S1470-2045(18)30569-2
- 383 29. Ahdoot M, Wilbur AR, Reese SE, et al. MRI-Targeted, Systematic, and Combined
384 Biopsy for Prostate Cancer Diagnosis. *N Engl J Med.* 2020;382(10):917-928.
385 doi:10.1056/NEJMoa1910038
- 386 30. Eklund M, Jäderling F, Discacciati A, et al. MRI-Targeted or Standard Biopsy in
387 Prostate Cancer Screening. *N Engl J Med.* 2021;385(10):908-920.
388 doi:10.1056/NEJMoa2100852
- 389 31. Hugosson J, Månsson M, Wallström J, et al. Prostate Cancer Screening with PSA and
390 MRI Followed by Targeted Biopsy Only. *N Engl J Med.* 2022;387(23):2126-2137.
391 doi:10.1056/NEJMoa2209454
- 392 32. Klotz L, Chin J, Black PC, et al. Comparison of Multiparametric Magnetic Resonance
393 Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for
394 Biopsy-Naive Men at Risk for Prostate Cancer. *JAMA Oncol.* 2021;7(4):534-542.
395 doi:10.1001/jamaoncol.2020.7589

- 396 33. Kerkmeijer LGW, Groen VH, Pos FJ, et al. Focal Boost to the Intraprostatic Tumor in
397 External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results
398 From the FLAME Randomized Phase III Trial. *J Clin Oncol Off J Am Soc Clin Oncol*.
399 2021;39(7):787-796. doi:10.1200/JCO.20.02873
- 400 34. Groen VH, Haustermans K, Pos FJ, et al. Patterns of Failure Following External Beam
401 Radiotherapy With or Without an Additional Focal Boost in the Randomized
402 Controlled FLAME Trial for Localized Prostate Cancer. *Eur Urol*. 2022;82(3):252-257.
403 doi:10.1016/j.eururo.2021.12.012
- 404 35. Dornisch AM, Zhong AY, Poon DMC, Tree AC, Seibert TM. Focal radiotherapy boost
405 to MR-visible tumor for prostate cancer: a systematic review. *World J Urol*.
406 2024;42(1):56. doi:10.1007/s00345-023-04745-w
- 407 36. Yamin G, Schenker-Ahmed NM, Shabaik A, et al. Voxel Level Radiologic–Pathologic
408 Validation of Restriction Spectrum Imaging Cellularity Index with Gleason Grade in
409 Prostate Cancer. *Clin Cancer Res*. 2016;22(11):2668-2674. doi:10.1158/1078-
410 0432.CCR-15-2429
- 411 37. James ND, Tannock I, N'Dow J, et al. The Lancet Commission on prostate cancer:
412 planning for the surge in cases. *Lancet Lond Engl*. 2024;403(10437):1683-1722.
413 doi:10.1016/S0140-6736(24)00651-2
- 414 38. Chatterjee A, Mercado C, Bourne RM, et al. Validation of Prostate Tissue
415 Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic
416 Findings. *Radiology*. 2022;302(2):368-377. doi:10.1148/radiol.2021204459
- 417 39. Singh S, Rogers H, Kanber B, et al. Avoiding Unnecessary Biopsy after
418 Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study.
419 *Radiology*. 2022;305(3):623-630. doi:10.1148/radiol.212536
- 420 40. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-
421 parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating
422 confirmatory study. *The Lancet*. 2017;389(10071):815-822. doi:10.1016/S0140-
423 6736(16)32401-1

424

Figures






Figure 2. Axial images of T_2 -weighted (T2W) MRI, conventional ADC, RSIs, RSIs overlaid on the anatomical T2W images, and whole-mount histopathology for three representative patients who underwent radical prostatectomy within 6 months of MRI. The RSI maps highlight the areas where clinically significant prostate cancer (csPCa) was confirmed on whole-mount histopathology. All three patients had PI-RADS 4 lesions in the peripheral zone (green arrows). Prostatectomy results showed that patient A had Gleason 4+4 prostate cancer (grade group 4), while patients B and C had Gleason 4+3 cancer (grade group 3).




Figure 3. ROC curves by grade group (GG) for patient-level detection of csPCa using RSIRs, PI-RADS and ADC. Patients were included if they were biopsy-naïve at time of MRI and underwent biopsy after MRI. Yellow circles correspond to PI-RADS thresholds. A) AUCs for discrimination of GG ≥ 2 PCa vs no csPCa (n=877). B) AUCs for GG2 PCa detection vs no csPCa (n=633). C) AUCs for GG3 PCa detection vs no csPCa (n=531). D) AUCs for GG4-5 PCa detection vs no csPCa (n=509). RSIRs was superior to ADC in detection of GG ≥ 2 PCa, GG2, GG3 and GG4-5 ($p < 0.01$). AUCs with 95% confidence intervals and p -values are in Supplementary Table 3.

Tables

Patient Characteristics. Total Study Participants (n = 1892)	
Cohorts	
UC San Diego Health	693
UC San Diego CTIPM	679
Harvard University's Massachusetts General Hospital (MGH)	64
University of Rochester Medical Center (URMC)	251
UC San Francisco (UCSF)	43
UT Health Sciences Center San Antonio (UTHSCSA)	147
University of Cambridge	15
Clinical Parameters	
Age (years), median (IQR)	70 (64-75)
PSA (ng/ml), median (SD)	6.36 (4.65-9.20)
Prostate volume (ml), median (IQR)	51 (36-74)
PSA density (ng/ml ²), median (IQR)	0.11 (0.07-0.19)
Biopsy	
Received biopsy prior to MRI scan	657
Biopsy-naïve at time of MRI scan (had a biopsy within 6 months after MRI)	1235 (877)
Pathology	
Systematic biopsy only	503
Targeted biopsy only	179
Systematic and targeted biopsy	710
Prostatectomy	323
No biopsy within 6 months of MRI scan	500
PI-RADS (v2.1)	
1	636
2	53
3	263
4	453
5	443
Not available*	44
Gleason Grade Group	
Benign	334
1	296
2	367
3	211
4	81
5	103
Race & Ethnicity	
White, Hispanic	94
White, Non-Hispanic	1228
White, Ethnicity Other / Unknown	65
Asian	120
Black or African American	117


American Indian/Alaska Native	6	
Native Hawaiian or Other Pacific Islander	6	
Other / Unknown	256	
Table 1. Characteristics of the patients included in this study. *Scans with no PI-RADS available were research-only scans. CTIPM = Center for Translational Imaging and Precision Medicine. UC = University of California. UT = University of Texas. PSA = prostate-specific antigen. PI-RADS = Prostate Imaging Reporting & Data System.		

	AUCs for csPCa discrimination in multivariable models			
Test Group	RSIrs	PI-RADS	ADC	RSIrs, PI-RADS*
A) GG \geq 2 cancer	0.72 [0.68-0.76]	0.74 [0.70-0.77]	0.54 [0.50-0.59]	0.77 [0.73-0.81]
B) GG2 cancer	0.69 [0.64-0.74]	0.69 [0.64-0.73]	0.53 [0.50-0.58]	0.73 [0.68-0.77]
C) GG3 cancer	0.72 [0.66-0.78]	0.74 [0.69-0.79]	0.54 [0.50-0.60]	0.78 [0.72-0.83]
D) GG4-5 cancer	0.80 [0.73-0.86]	0.85 [0.80-0.89]	0.58 [0.51-0.65]	0.87 [0.82-0.92]
	PSA, Age	PSAD, Age, RSIrs	PSAD, Age, RSIrs, PI-RADS*	PSAD, Age, Race, RSIrs, PI-RADS*
A) GG \geq 2 cancer	0.61 [0.56-0.66]	0.74 [0.70-0.77]	0.78 [0.74-0.82]	0.78 [0.74-0.82]
B) GG2 cancer	0.53 [0.50-0.58]	0.69 [0.64-0.74]	0.73 [0.69-0.78]	0.74 [0.69-0.78]
C) GG3 cancer	0.65 [0.57-0.72]	0.73 [0.67-0.79]	0.78 [0.72-0.83]	0.78 [0.72-0.83]
D) GG4-5 cancer	0.77 [0.70-0.83]	0.86 [0.81-0.91]	0.90 [0.85-0.94]	0.90 [0.85-0.94]

PSAD: prostate specific antigen density
 *: Performance in predictor groups marked with an asterisk is significantly better than that of RSIrs.

Table 2. Results from the multivariable logistic regression models for combinations of RSIrs with clinical and imaging parameters for discrimination of clinically significant prostate cancer (csPCa, grade group [GG] \geq 2). Group A) independent testing in all biopsy-naïve patients at time of MRI with biopsy confirmed diagnosis who were not used for training (n=664); comparison is csPCa vs. no csPCa (benign or grade group 1, GG1). Group B) GG2 vs. non-csPCa: subset of independent testing dataset with either GG2 csPCa or no csPCa (n=500). Group C) GG3 vs. non-csPCa: subset of independent testing dataset with either GG3 csPCa or no csPCa (n=409). Group D) GG4-5 vs. no csPCa: subset of independent testing dataset with GG4 csPCa, GG5 csPCa, or no csPCa (n=393). 95% confidence intervals were calculated from 10,000-bootstraping stratified by csPCa.

Supplementary Material



Supplementary Figure 1. A) Histogram of RSIs values in all patients in the study. B) Histogram of RSIs values in patients who were biopsy-naïve at time of MRI.

428
429

RSI model formula	RSI compartment	Fixed Diffusion Coefficient (s/mm ²)
$S(b) = \sum_{i=1}^4 C_i e^{-bD_i}$	Restricted Diffusion (C_1)	$1.1 * 10^{-4}$ (D_1)
	Hindered Diffusion (C_2)	$1.8 * 10^{-3}$ (D_2)
	Free Diffusion (C_3)	$3.6 * 10^{-3}$ (D_3)
	Vascular Flow (C_4)	0.1220 (D_4)

Supplementary Table 1. The RSI model computes the sum of DWI signal from the four compartments as expressed by the formula above. $S(b)$ represents the measured diffusion-weighted imaging (DWI) signal intensity at a specific b -value. The signal is modeled as a linear combination of exponential decays, each corresponding to one of four diffusion compartments. C_i denotes the signal contribution of a particular compartment to the overall signal; these contributions are determined through model-fitting. The diffusion coefficients, D_i , are set to empirically determined values for each of the four tissue compartments (C_i).

430
431
432
433

UCSD CTIPM	DWI	T₂-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4500	7000
TE (ms)	69	100
FOV (mm)	240 x 120	240 x 240
Matrix [resampled dimensions]	96 x 48 [128 x 128]	320 x 320 [512 x 512]
Slices	16	32
Slice Thickness (mm)	6	3
<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[6], 1000[6], 2000[12]	N/A
Field Strength (T)	3	3

UCSD Health	DWI	T₂-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4000	5300
TE (ms)	69	100
FOV (mm)	240 x 120	200 x 200
Matrix [resampled dimensions]	96 x 48 [256 x 256]	320 x 320 [512 x 512]
Slices	16	32
Slice Thickness (mm)	6	3
<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[8], 1000[8], 2000[16]	N/A
Field Strength (T)	3	3

URMC	DWI	T₂-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	3800	4800
TE (ms)	85	104
FOV (mm)	52 x 52	180x180
Matrix [resampled dimensions]	100 x 52 [104 x 200]	384 x 365 [384 x 384]
Slices	22	32
Slice Thickness (mm)	4	3
<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[6], 1000[6], 2000[6]	N/A
Field Strength (T)	3	3

MGH	DWI	T₂-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4500	3937
TE (ms)	59	169
FOV (mm)	240 x 120	160 x 160
Matrix [resampled dimensions]	96 x 48 [128x128]	360 x 224 [1024 x 1024]
Slices	16	40
Slice Thickness (mm)	6	3
<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[6], 1000[6], 2000[12]	N/A
Field Strength (T)	3	3

Cambridge	DWI	T₂-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)

TR (ms)	4500	3130
TE (ms)	68	98
FOV (mm)	220 x 110	180 x 180
Matrix [resampled dimensions]	96 x 48 [256 x 256]	448 x 256 [512 x 512]
Slices	8	30
Slice Thickness (mm)	4	3
<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[2], 1000[2], 2000[4]	N/A
Field Strength (T)	3	3
UTHSCSA	DWI	T₂-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	6300	4710
TE (ms)	105	100
FOV (mm)	52 x 100	180 x 180
Matrix [resampled dimensions]	52 x 100 x [104 x 200]	240 x 320 x [320 x 320]
Slices	22	30
Slice Thickness (mm)	4	3
<i>b</i> -values (s/mm ²) [number of samples]	0[1], 500[6], 1000[18], 2000[42]	N/A
Field Strength (T)	3	3
UCSF	DWI	T₂-weighted
Pulse sequence	Diffusion-weighted EPI	Fast Spin Echo (FSE)
TR (ms)	4500	2964
TE (ms)	73	150
FOV (mm)	200 x 200	220 x 220
Matrix [resampled dimensions]	256 x 256 [256 x 256]	512 x 512 [320 x 320]
Slices	35	36
Slice Thickness (mm)	3	3
<i>b</i> -values (s/mm ²) [number of samples]	0[5], 100[6], 800[12], 1400[12], 2500[18]	N/A
Field Strength (T)	3	3
Institution	Scanner models	Number of Stations
UCSD CTIPM	GE Healthcare Discovery MR750, GE Healthcare Signa Premier	4
UCSD Health	GE Healthcare Discovery MR750, GE Healthcare Signa Premier	4
URMC	SIEMENS Skyra	2
MGH	GE Healthcare Signa Premier	1
UCSF	GE Healthcare Signa Premier	2
Cambridge	GE Healthcare Discovery MR750	1
UTHSCSA	SIEMENS Skyra	3
Total	3 scanner models	17 stations

Supplementary Table 2. MRI acquisition parameters for each cohort. Parameters such as echo time (TE), repetition time (TR), matrix acquisition or slice thickness differ between RSI protocols. FOV: field-of-view. FSE: fast spin echo. EPI: echo-planar imaging. DWI: diffusion-weighted imaging. UCSD: University of California San Diego. CTIPM: Center for Translational Imaging and Precision Medicine. MGH: Harvard University's Massachusetts General Hospital. URMC: University of Rochester Medical Center. UTHSCSA: University

of Texas Health Sciences Center San Antonio. UCSF: University of California San Francisco. Cambridge: University of Cambridge.

434
435
436

Patient Cohort	n	% with csPCa	AUC RSIRs	AUC PI-RADS	AUC ADC
GG ≥ 2	877	55	0.73 [0.69,0.76]	0.75 [0.71,0.78]	0.54 [0.50,0.57]
GG ≥ 3	642	38	0.76 [0.72,0.80]	0.79 [0.76,0.82]	0.55 [0.50,0.60]
GG 2 only	633	37	0.69 [0.65,0.73]	0.70 [0.66,0.74]	0.52 [0.48,0.57]
GG 3 only	531	25	0.73 [0.68,0.77]	0.75 [0.71,0.80]	0.53 [0.48,0.59]
GG 4-5 only	509	22	0.80 [0.74,0.85]	0.83 [0.79,0.87]	0.57 [0.51,0.63]
TZ csPCa	329	43	0.72 [0.66,0.78]	0.72 [0.66,0.77]	0.57 [0.51,0.63]
PZ csPCa	602	55	0.72 [0.68,0.76]	0.76 [0.73,0.80]	0.52 [0.48,0.57]
< 60 years old	103	45	0.79 [0.69,0.87]	0.70 [0.60,0.79]	0.57 [0.45,0.68]
≥ 60 years old	772	56	0.72 [0.68,0.75]	0.75 [0.72,0.78]	0.53 [0.49,0.57]
Race White	672	53	0.74 [0.70,0.77]	0.76 [0.72,0.79]	0.54 [0.49,0.58]
Race Asian	47	64	0.74 [0.59,0.87]	0.78 [0.64,0.89]	0.62 [0.44,0.79]
Race Black	51	45	0.68 [0.53,0.82]	0.60 [0.46,0.74]	0.54 [0.38,0.70]
Race Other / Unknown	107	64	0.70 [0.59,0.80]	0.72 [0.62,0.80]	0.57 [0.45,0.68]

	<i>p</i> -value RSIRs vs. PI-RADS	<i>p</i> -value RSIRs vs. ADC
GG ≥ 2	0.31	<0.01
GG ≥ 3	0.14	<0.01
GG 2 only	0.75	<0.01
GG 3 only	0.31	<0.01
GG 4-5 only	0.20	<0.01
TZ csPCa	0.90	<0.01
PZ csPCa	0.07	<0.01
< 60 years old	0.12	<0.01
≥ 60 years old	0.11	<0.01
Race White	0.32	<0.01
Race Asian	0.61	0.28
Race Black	0.41	0.12
Race Other / Unknown	0.82	0.05

Supplementary Table 3. AUC values for RSIRs, PI-RADS and ADC in different subsets. 95% confidence intervals were calculated from 10,000-bootstraping stratified by grade group. All cohorts are against non-csPCa (benign and grade group 1). GG: Grade Group.

437
438
439